Bob Nelsen (Photo by Michael Kovac/Getty Images)

With stars aligned and cash in re­serve, Bob Nelsen's Re­silience plans a makeover at 2 new fa­cil­i­ty ad­di­tions to its drug man­u­fac­tur­ing up­start

Bob Nelsen’s new, state-of-the-art drug man­u­fac­tur­ing ini­tia­tive is tak­ing shape.

Just 3 months af­ter gath­er­ing $800 mil­lion of launch mon­ey, a dream team board and a plan to shake up a field where he found too many bot­tle­necks and in­ef­fi­cien­cies for the era of Covid-19, Re­silience has snapped up a pair of fa­cil­i­ties now in line for a re­tool­ing.

The com­pa­ny has ac­quired a 310,000-square-foot plant in Boston from Sanofi along with a 136,000-square-foot plant in On­tario to add to a net­work which CEO Rahul Singhvi says is just get­ting start­ed on build­ing his com­pa­ny’s op­er­a­tions up. The Sanofi deal comes with a con­tract to con­tin­ue man­u­fac­tur­ing one of its drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.